Related Experiment Video
Updated: Aug 6, 2026

09:36
Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
Published on: June 28, 2019
Dopamine Compensates for Amyloid-Induced Default Mode Network Dysfunction to Support Learning
Joseph Giorgio1,2,3, Thomas M Morin4,5, Hsiang-Yu Chen4
1Department of Neuroscience, University of California, Berkeley, CA, USA.
Biorxiv : the Preprint Server for Biology
|July 17, 2026
Summary
Beta-amyloid (Aβ) accumulation impairs learning in preclinical Alzheimer's disease (AD). However, higher dopamine levels in the brain can restore learning by rebalancing neural network connectivity.
Area of Science:
- Neuroscience
- Cognitive Science
- Medical Imaging
Background:
- Preclinical Alzheimer's disease (AD) involves beta-amyloid (Aβ) accumulation in the default mode network (DMN).
- The functional and behavioral impacts of Aβ burden in the DMN are not well understood.
Purpose of the Study:
- To investigate how Aβ impacts learning and neural network function in cognitively normal older adults.
- To explore the role of dopamine in compensating for Aβ-related learning deficits.
Main Methods:
- Task-based functional magnetic resonance imaging (fMRI).
- Positron emission tomography (PET) for Aβ, tau, and dopamine.
- Computational modeling of effective connectivity.
Main Results:
- Aβ burden impaired learning independently of tau, but this was reversed by higher dorsolateral striatal dopamine synthesis.
- Individuals with Aβ showed reduced DMN activity in response to error feedback, correlating with poorer learning.
- Aβ disrupted DMN effective connectivity during error processing, which was counteracted by dopamine.
Conclusions:
- Aβ impairs learning by disrupting DMN modulation during feedback.
- Dopamine synthesis capacity can partially compensate for Aβ-related learning disruptions by rebalancing frontostriatal network connectivity.
- Dopamine-dependent network rebalancing may support cognitive resilience for learning in preclinical AD.
Related Concept Videos
Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Long-term Depression
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...
Calcium Ion Concentration Mechanism
If over time, all...
Long-term Depression
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

